Resource Latest COVID-19 updates All NRAS updates on COVID-19 will be included in this section. This will include updates on NRAS and what we are doing about the COVID-19 pandemic and more general updates from leading health organisations on the latest information and advice for RA patients. Print Article FAQs on New Antiviral Treatment Who is eligible for the treatment? The official list of those eligible can be found in appendix 1 of the clinical commissioning policy published on the 24th of December 2021. See the full, published policy here. With regards to rheumatoid arthritis and immune-mediated inflammatory disorders, the following have been identified: IMID treated with rituximab or other […] News, 23 Dec COVID-19 Update: Hope on the horizon for immuno-suppressed/compromised individuals December update on COVID-19 anti-viral medications and monoclonal antibody treatments as well as updates on 3rd primary doses and boosters. On 22nd December we hosted a panel discussion on the COVID treatments now available across the UK for those with immune mediated conditions such as RA. Watch the full video below or on our Youtube […] Article Reflections on how COVID has changed the health landscape Reflections on how COVID has changed the health landscape and highlighted the importance of supported self-management By Ailsa Bosworth, MBE As we begin 2022, I’ve taken time out to reflect on what has happened in healthcare delivery generally, but especially within rheumatology, and many of you will be aware that we have produced resources to […] News, 10 Dec Covid update: new treatment Announcement A press release has been issued relating to antiviral treatments for COVID-19. The following two announcements have been made: -There will be an antivirals trial for those testing positive with covid. This will be available to everyone over 50 and those with specific health conditions. Please refer to the link in this article to see […] News, 02 Dec The Third Vaccine Patients who are eligible Based on the Joint Committee on Vaccination and Immunisation (JCVI) recommendations, nearly all rheumatology patients (aside from those solely on hydroxychloroquine or sulfasalazine), should receive a third dose of the vaccine. Patients on a dose of Methotrexate lower than 20mg are also not eligible. Read the full independent report by the JCVI here. Who will contact Patients A letter […] News, 02 Dec Ending the Shielding Programme The decision to end shielding At the start of the COVID-19 pandemic, shielding was introduced as one of the few ways to support those who, at the time, were considered clinically extremely vulnerable (CEV). It was the right decision at the time, but we know that shielding advice is extremely restrictive and can have a significant […] News, 31 Aug The OCTAVE study results The OCTAVE study results were released on 24 August 2021 and we realise that the initial headlines could cause concern and worry. The study looked at vaccine response of those who are ‘immuno-compromised’ which includes a very wide range of people at varying levels of immune-compression. What the study has shown is that compared to people […] Article Guidance for NRAS groups on resuming in-person events Guidance on when NRAS groups may choose to resume face to face meetings (at their own risk and dependent on the profile of their members/the location/the activity) Article Information about Coronavirus (COVID-19) Commonly asked questions about government guidelines and vaccines.
Article FAQs on New Antiviral Treatment Who is eligible for the treatment? The official list of those eligible can be found in appendix 1 of the clinical commissioning policy published on the 24th of December 2021. See the full, published policy here. With regards to rheumatoid arthritis and immune-mediated inflammatory disorders, the following have been identified: IMID treated with rituximab or other […]
Article FAQs on New Antiviral Treatment Who is eligible for the treatment? The official list of those eligible can be found in appendix 1 of the clinical commissioning policy published on the 24th of December 2021. See the full, published policy here. With regards to rheumatoid arthritis and immune-mediated inflammatory disorders, the following have been identified: IMID treated with rituximab or other […]
News, 23 Dec COVID-19 Update: Hope on the horizon for immuno-suppressed/compromised individuals December update on COVID-19 anti-viral medications and monoclonal antibody treatments as well as updates on 3rd primary doses and boosters. On 22nd December we hosted a panel discussion on the COVID treatments now available across the UK for those with immune mediated conditions such as RA. Watch the full video below or on our Youtube […]
News, 23 Dec COVID-19 Update: Hope on the horizon for immuno-suppressed/compromised individuals December update on COVID-19 anti-viral medications and monoclonal antibody treatments as well as updates on 3rd primary doses and boosters. On 22nd December we hosted a panel discussion on the COVID treatments now available across the UK for those with immune mediated conditions such as RA. Watch the full video below or on our Youtube […]
Article Reflections on how COVID has changed the health landscape Reflections on how COVID has changed the health landscape and highlighted the importance of supported self-management By Ailsa Bosworth, MBE As we begin 2022, I’ve taken time out to reflect on what has happened in healthcare delivery generally, but especially within rheumatology, and many of you will be aware that we have produced resources to […]
Article Reflections on how COVID has changed the health landscape Reflections on how COVID has changed the health landscape and highlighted the importance of supported self-management By Ailsa Bosworth, MBE As we begin 2022, I’ve taken time out to reflect on what has happened in healthcare delivery generally, but especially within rheumatology, and many of you will be aware that we have produced resources to […]
News, 10 Dec Covid update: new treatment Announcement A press release has been issued relating to antiviral treatments for COVID-19. The following two announcements have been made: -There will be an antivirals trial for those testing positive with covid. This will be available to everyone over 50 and those with specific health conditions. Please refer to the link in this article to see […]
News, 10 Dec Covid update: new treatment Announcement A press release has been issued relating to antiviral treatments for COVID-19. The following two announcements have been made: -There will be an antivirals trial for those testing positive with covid. This will be available to everyone over 50 and those with specific health conditions. Please refer to the link in this article to see […]
News, 02 Dec The Third Vaccine Patients who are eligible Based on the Joint Committee on Vaccination and Immunisation (JCVI) recommendations, nearly all rheumatology patients (aside from those solely on hydroxychloroquine or sulfasalazine), should receive a third dose of the vaccine. Patients on a dose of Methotrexate lower than 20mg are also not eligible. Read the full independent report by the JCVI here. Who will contact Patients A letter […]
News, 02 Dec The Third Vaccine Patients who are eligible Based on the Joint Committee on Vaccination and Immunisation (JCVI) recommendations, nearly all rheumatology patients (aside from those solely on hydroxychloroquine or sulfasalazine), should receive a third dose of the vaccine. Patients on a dose of Methotrexate lower than 20mg are also not eligible. Read the full independent report by the JCVI here. Who will contact Patients A letter […]
News, 02 Dec Ending the Shielding Programme The decision to end shielding At the start of the COVID-19 pandemic, shielding was introduced as one of the few ways to support those who, at the time, were considered clinically extremely vulnerable (CEV). It was the right decision at the time, but we know that shielding advice is extremely restrictive and can have a significant […]
News, 02 Dec Ending the Shielding Programme The decision to end shielding At the start of the COVID-19 pandemic, shielding was introduced as one of the few ways to support those who, at the time, were considered clinically extremely vulnerable (CEV). It was the right decision at the time, but we know that shielding advice is extremely restrictive and can have a significant […]
News, 31 Aug The OCTAVE study results The OCTAVE study results were released on 24 August 2021 and we realise that the initial headlines could cause concern and worry. The study looked at vaccine response of those who are ‘immuno-compromised’ which includes a very wide range of people at varying levels of immune-compression. What the study has shown is that compared to people […]
News, 31 Aug The OCTAVE study results The OCTAVE study results were released on 24 August 2021 and we realise that the initial headlines could cause concern and worry. The study looked at vaccine response of those who are ‘immuno-compromised’ which includes a very wide range of people at varying levels of immune-compression. What the study has shown is that compared to people […]
Article Guidance for NRAS groups on resuming in-person events Guidance on when NRAS groups may choose to resume face to face meetings (at their own risk and dependent on the profile of their members/the location/the activity)
Article Guidance for NRAS groups on resuming in-person events Guidance on when NRAS groups may choose to resume face to face meetings (at their own risk and dependent on the profile of their members/the location/the activity)
Article Information about Coronavirus (COVID-19) Commonly asked questions about government guidelines and vaccines.
Article Information about Coronavirus (COVID-19) Commonly asked questions about government guidelines and vaccines.